

CERTIFICATE

Survey of 25 May 2018

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis 01 - TPT, INR, aPTT (221):

Validity 6 months:

aPTT (R: B1a)

TPZ INR (R: B1a)

Haemostasis 02 - FIB, TZ, FSP (222):

Validity 12 months:

Fibrinogen

Thrombin Time

Haemostasis 05 - AT, Protein C, Protein S, C1-Inhibitor (225):

Validity 12 months:

Antithrombin

free Protein S immun. (conc.)

total Protein C

free Protein S funct. (act.)

Protein S total

Haemostasis 06 - D-Dimer (226):

Validity 12 months:

D-Dimer (qual)

D-Dimer (quant.)

(R) analysis is subject to the RiliBÄK

Participant:

2430

MUDr., PhD. Martin Spacek

Vseobecná fakultní nemocnice v Praze

Centrální hematologické laboratorie ULBLD

U Nemocnice 2

12808 Praha 2



Düsseldorf, 30 July 2018

Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)

CERTIFICATE

Survey of 25 May 2018

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis 07 - Factor VIII, WF (227):

Validity 12 months:

Faktor VIII akt.

Willebrand Fact. Ag

Willebrand Fact. RiCof

Haemostasis 20 - Functional APC Resistance (288):

Validity 12 months:

diagnostic comments

(R) analysis is subject to the RiliBÄK

Participant:

2430

MUDr., PhD. Martin Spacek

Vseobecna fakultni nemocnice v Praze


Centralni hematologicke laboratore ULBLD

U Nemocnice 2

12808 Praha 2



Düsseldorf, 30 July 2018



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)

CERTIFICATE OF PARTICIPATION

Survey of 25 May 2018

You have participated in the External Quality Assessment with the following analysis

Haemostasis 01 - TPT, INR, aPTT (221):

aPTT (R: B1a) TPZ INR (R: B1a)

Haemostasis 02 - FIB, TZ, FSP (222):

Fibrinogen Thrombin Time

Haemostasis 05 - AT, Protein C, Protein S, C1-Inhibitor (225):

Antithrombin free Protein S immun. (conc.) total Protein C
free Protein S funct. (act.) Protein S total

Haemostasis 06 - D-Dimer (226):

D-Dimer (qual) D-Dimer (quant.)

Haemostasis 07 - Factor VIII, WF (227):

Faktor VIII akt. Willebrand Fact. Ag Willebrand Fact. RiCof

(R) analysis is subject to the RiliBÄK

Participant:

2430
MUDr., PhD. Martin Spacek
Vseobecná fakultní nemocnice v Praze
Centrální hematologické laboratorie ULBLD
U Nemocnice 2
12808 Praha 2



Düsseldorf, 30 July 2018

Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)

CERTIFICATE OF PARTICIPATION

Survey of 25 May 2018

You have participated in the External Quality Assessment with the following analysis

Haemostasis 20 - Functional APC Resistance (288):

APC Resistance

diagnostic comments

(R) analysis is subject to the RiliBÄK

Participant:

2430

MUDr., PhD. Martin Spacek


Vseobecna fakultni nemocnice v Praze

Centralni hematologicke laboratore ULBLD

U Nemocnice 2

12808 Praha 2

Düsseldorf, 30 July 2018



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)

